Edition:
United Kingdom

GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease


Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Global Blood Therapeutics Inc ::GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD).